Article

Treatment with anti-gamma-glutamyl transpeptidase antibody attenuates osteolysis in collagen-induced arthritis mice.

Applied Cell Biotechnologies, Yokohama, Kanagawa, Japan.
Journal of Bone and Mineral Research (Impact Factor: 6.13). 01/2008; 22(12):1933-42. DOI: 10.1359/jbmr.070726
Source: PubMed

ABSTRACT The effectiveness of a new antibody treatment on arthritis-associated osteolysis was studied by using CIA mice. GGT, a newly identified bone-resorbing factor, was upregulated in arthritic joints. We generated monoclonal antibodies against GGT and injected them into CIA mice. Mice treated with antibodies showed a reduction in osteoclast number and bone erosion.
Gamma-glutamyl transpeptidase (GGT) acts as a bone-resorbing factor that stimulates osteoclast formation. GGT expression has been detected in active lymphocytes that accumulate at inflammation sites, such as rheumatoid arthritis (RA). We hypothesize that GGT is an effective target for suppression of arthritis-related osteoclastogenesis and joint destruction. Here, we describe the therapeutic effect of neutralizing antibodies against GGT on joint destruction using a collagen-induced arthritis (CIA) mouse model.
GGT expression in the synovium of RA patients and CIA mice was determined by immunohistochemistry and RT-PCR. Monoclonal antibodies were generated against recombinant human GGT (GGT-mAbs) using BALB/c mice. Antibody treatment was performed by intraperitoneal injections of GGT-mAbs into CIA mice. Effects of antibody treatment on arthritis and bone erosion were evaluated by incidence score, arthritis score, and histopathological observations. The role of GGT in osteoclast development was examined by using the established osteoclastogenic culture system.
GGT expression was significantly upregulated in inflamed synovium. Immunohistochemistry revealed that GGT was present in lymphocytes, plasma cells, and macrophages, as well as capillaries. Injection of GGT-mAbs significantly decreased the number of osteoclasts and attenuated the severity of joint destruction in CIA mice. In vitro examination showed that GGT enhanced RANKL-dependent osteoclast formation. GGT stimulated the expression of RANKL in osteoblasts and its receptor RANK in osteoclast precursors, respectively.
This study indicates that inflamed synovial tissue-derived GGT acts as a risk factor for joint destruction and that the antibody-mediated inhibition of GGT significantly decreases osteoclast number and bone erosion in CIA mice. GGT antagonists might be novel therapeutic agents for attenuating joint destruction in RA patients.

0 Bookmarks
 · 
81 Views
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Oxygen metabolism has an important role in the pathogenesis of rheumatoid arthritis. A certain correlation was observed between oxidative stress, arthritis and the immune system. Reactive oxygen species produced in the course of cellular oxidative phosphorylation and by activated phagocytic cells during oxidative burst, exceed the physiological buffering capacity and result in oxidative stress. The excessive production of ROS can damage protein, lipids, nucleic acids, and matrix components. Patients with rheumatoid arthritis have an altered antioxidant defense capacity barrier. In the present study the effect of substances with antioxidative properties, i.e. pinosylvin and carnosine, was determined in monotherapy for the treatment of adjuvant arthritis (AA). Moreover carnosine was evaluated in combination therapy with methotrexate. Rats with AA were administered first pinosylvin (30 mg/kg body mass daily per os), second carnosine (150 mg/kg body mass daily per os) in monotherapy for a period of 28 days. Further, rats with AA were administered methotrexate (0.3 mg/kg body mass 2-times weekly per os), and a combination of methotrexate+carnosine, with the carnosine dose being the same as in the previous experiment. Parameters, i.e. changes in hind paw volume and arthritic score were determined in rats as indicators of destructive arthritis-associated clinical changes. Plasmatic levels of TBARS and lag time of Fe(2+)-induced lipid peroxidation (tau-FeLP) in plasma and brain were specified as markers of oxidation. Plasmatic level of CRP and activity of γ-glutamyltransferase (GGT) in spleen and joint were used as inflammation markers. In comparison to pinosylvin, administration of carnosine monotherapy led to a significant decrease in the majority of the parameters studied. In the combination treatment with methotrexate+carnosine most parameters monitored were improved more remarkably than by methotrexate alone. Carnosine can increase the disease-modifying effect of methotrexate treatment in rat AA.
    Interdisciplinary toxicology 06/2012; 5(2):84-91.
  • [Show abstract] [Hide abstract]
    ABSTRACT: Glutathione is one of the most abundant proteins in vivo involved in maintaining cellular homeostasis and is essential for the regulation of oxidant stress. Gamma-Glutamyl transferase (GGT) is the first enzyme of the gamma glutamyl cycle that regulates the antioxidant glutathione, hence it is a critical enzyme in glutathione homeostasis. Recent findings have indicated upregulation of GGT in inflammation, increasing antioxidant defence whilst potentially driving leukotriene-induced inflammation. GGT is a marker of future comorbid diseases consistent with inflammation (and oxidative stress) as a key central pathophysiological process. COPD reflects several distinct pathological phenotypes. Inflammation (and hence oxidative stress) is influenced by other factors such as bacterial colonisation and exacerbations. The increased incidence of other co-morbid conditions with systemic inflammation suggests that common pathophysiological processes are responsible. Active oxidant stress and hence the role of GGT may play a role in these processes. Future studies of systemic and local GGT function and genotypes in well characterised patients may lead to a better understanding of the processes involved and hence the development of new treatment strategies.
    COPD Journal of Chronic Obstructive Pulmonary Disease 08/2010; 7(4):285-90. · 2.31 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Lipopolysaccharide (LPS) from periodontal pathogens is one of the main causes of alveolar bone destruction. Prostaglandin E(2) (PGE(2)) produced by host cells after LPS stimulation may contribute to the bone destruction. PGE(2) regulates osteoblast-mediated osteoclastogenesis via PGE-specific receptor 4 (EP4). We examined the effects of the PGE(2)-EP4 pathway on the expression of osteoclastogenesis-related factors and studied the inhibitory effect of orally administered EP4-specific antagonist (EP4A) on LPS-induced bone destruction compared to complete inhibition of endogenous PGE(2) by indomethacin (IND). ST2 cells were treated with IND or EP4A and stimulated by LPS. The mRNA expressions of interleukin-6 (IL-6), tumor necrosis factor-α (TNF-α), the receptor activator of nuclear factor-κB ligand (RANKL), and osteoprotegerin in ST2 cells were examined by quantitative reverse transcription-polymerase chain reaction. LPS-induced bone destruction was examined using a rat model for the periodontal tissue destruction with topically applied LPS. IND and EP4A inhibited the upregulation of TNF-α mRNA expression, and only EP4A inhibited IL-6 and RANKL mRNA expressions in ST2 cells with LPS stimulation. Topically applied LPS induced a two-phase increase in osteoclasts along the alveolar bone margin, peaking after 3 hours and 3 days. Oral administration of EP4A and IND downregulated the later phase increase of osteoclasts. However, the early phase of increase at 3 hours was upregulated in IND-treated rats but not in EP4A-treated rats. It appears that the PGE(2)-EP4 pathway has an important role in LPS-induced osteoclastogenesis, and the specific blocking of the PGE(2)-EP4 pathway by EP4A can effectively downregulate bone destruction caused by LPS without an unexpected increased number of osteoclasts.
    Journal of Periodontology 09/2011; 83(4):506-13. · 2.40 Impact Factor

Full-text

View
0 Downloads